Related content

Second-line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: A phase II trial

By Tas Faruk   Demir Cumhur   Camlica Hakan   Ustuner Zeki   Topuz Erkan  

Medical Oncology, Vol. 21, Iss. 3, 2004-09 ,pp. : 233-240

Humana Press, Inc

Access to resources Recommend Favorite

Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer

By Feliu J.   Martín G.   Castro J.   Sundlov A.   Rodriguez-Jaráiz A.   Casado E.   Lomas M.   Madroñal C.   Galán A.   Belda C.   Gonzalez-Barón M.  

Cancer Chemotherapy and Pharmacology, Vol. 58, Iss. 4, 2006-10 ,pp. : 527-531

Springer Publishing Company

Access to resources Recommend Favorite

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG0803)

By Wu Y.-L.   Zhou C.   Cheng Y.   Lu S.   Chen G.-Y.   Huang C.   Huang Y.-S.   Yan H.-H.   Ren S.   Liu Y.   Yang J.-J.  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 993-999

Oxford University Press

Access to resources Recommend Favorite

Comparison of docetaxel/cisplatin dosages of 75/60 and 60/60 mg/m2 for the treatment of non-small cell lung cancer

By                        

Experimental and Therapeutic Medicine, Vol. 4, Iss. 2, 2012-01 ,pp. : 317-322

Spandidos Publications

Access to resources Recommend Favorite

High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy

By Arrieta Oscar  

Medical Oncology, Vol. 28, Iss. 1, 2011-03 ,pp. : 300-306

Humana Press, Inc

Access to resources Recommend Favorite